

BMJ Open

Economic inequalities in burden of illness, diagnosis and treatment of five long-term conditions in England: panel study.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005530.R2
Article Type:	Research
Date Submitted by the Author:	n/a
Complete List of Authors:	Steel, Nicholas; University of East Anglia Hardcastle, Antonia; University of East Anglia, Norwich Medical School Bachmann, Max; Univeristy of East Anglia, School of Medicine, Health Policy and Practic Richards, Suzanne; University of Exeter Medical School, Mounce, Luke; University of Exeter Medical School, Clark, Allan; University of East Anglia, Norwich Medical School Lang, Iain; PenCLAHRC, Melzer, David; University of Exeter Medical School, Campbell, John; University of Exeter, Primary Care;
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Health services research, Epidemiology, Public health, Sociology
Keywords:	Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, EPIDEMIOLOGY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3
4 **Economic inequalities in burden of illness, diagnosis and**
5 **treatment of five long-term conditions in England: panel study.**
6
7
8

9
10 Steel N, Hardcastle A, Bachmann MO, Richards S, Mounce L, Clark A, Lang I, Melzer D,
11 Campbell J.

12
13 N Steel, Clinical Reader¹

14 AC Hardcastle, Senior Research Associate¹

15 MO Bachmann, Professor of Health Services Research¹

16 S H Richards, Senior Lecturer²

17 LTA Mounce, Research Associate²

18 A Clark, Senior Lecturer¹

19 I Lang, Senior Lecturer in Public Health³

20 D Melzer, Professor of Epidemiology and Public Health²

21 J Campbell, Professor of General Practice and Primary Care²

22
23
24 ¹Population Health and Primary Care, Norwich Medical School, University of East Anglia,
25 Norwich NR4 7TJ

26
27 ²University of Exeter Medical School, Smeall Building, St Luke's Campus, Exeter, EX1 2LU

28
29 ³NIHR CLAHRC South West Peninsula, Veysey Building, Salmon Pool Lane, Exeter, EX2
30 4SG

31
32
33 Corresponding author: Nicholas Steel

34 n.steel@uea.ac.uk

35 01603 591161
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective:

We compared the distribution by wealth of self-reported illness burden (estimated from validated scales, biomarker and reported symptoms) for angina, cataract, depression, diabetes and osteoarthritis, with the distribution of self-reported medical diagnosis and treatment. We aimed to determine if the greater illness burden borne by poorer participants was matched by appropriately higher levels of diagnosis and treatment.

Design:

The English Longitudinal Study of Ageing, a panel study of 12,765 participants aged 50 years and older in four waves from 2004 to 2011, selected using a stratified random sample of households in England. Distribution of illness burden, diagnosis and treatment by wealth was estimated using regression analysis.

Outcome measures:

The main outcome measures were odds ratios (ORs) for the illness burden, diagnosis and treatment respectively, adjusted for age, sex and wealth. We estimated the illness burden for angina with the Rose Angina scale, diabetes with fasting glycosylated haemoglobin, depression with the Centre for Epidemiologic Studies Depression Scale, osteoarthritis with self-reported pain and disability, and cataract with self-reported poor vision. Medical diagnoses were self-reported for all conditions. Treatment was defined as beta-blocker prescription for angina, surgery for osteoarthritis and cataract, and receipt of pre-defined effective interventions for diabetes and depression.

Results:

Compared to the wealthiest, the least wealthy participant had substantially higher odds for illness burden from any of the five conditions at all four time points, with odds ratios ranging from 4.2 (95% confidence interval 2.6 to 6.8) for diabetes to 15.1 (11.4 to 20.0) for osteoarthritis. The odds ratios for diagnosis and treatment were smaller in all 5 conditions, and ranged from 0.9 (0.5 to 1.4) for diabetes treatment to 4.5 (3.3 to 6.0) for angina diagnosis.

Conclusions:

The substantially higher illness burden in less wealthy participants was not matched by appropriately higher levels of diagnosis and treatment.

Strengths and limitations of this study

- The English Longitudinal Study of Ageing (ELSA) is a unique single source of detailed data on socioeconomic status and health, and this is the first study to compare inequalities in illness burden, self-reported medical diagnosis and treatment of long-term conditions in a panel study over time
- Highly detailed measures of individual wealth were used alongside standardised scales and blood biomarker to assess the illness burden of depression, angina and diabetes
- Standardised scales were not included in ELSA for osteoarthritis and cataract, so assessment of illness burden for these two conditions was based on attributed symptoms which were not specific for osteoarthritis and cataract
- The study used self-reported data collected using an extensively tested structured questionnaire, but no information from medical records was collected
- An analysis of pooled data from 4 waves of ELSA was used to maximise the sample size, and the main finding that less wealthy participants are relatively underdiagnosed requires validation in a larger longitudinal study.

Main text

Introduction

Poverty is associated with poor health, poor access to health care and poor health outcomes in many countries and across different health care systems¹⁻³. Much of this variation is caused by recognised broad social determinants of health⁴. Considerable political effort has been directed at attempts to narrow health inequalities by reducing poverty and social exclusion. However, as health care has become more effective at improving health, its potential contribution to ameliorating health inequalities has increased. McKeown demonstrated in the 1970s that health services had contributed little to health improvement⁵, but the same claim could not be made today. The past 30 years have seen the introduction of a wide range of effective interventions, particularly for the prevention and management of chronic disease⁶. Yet although these new interventions improve health, they are not necessarily applied equally across the population. Health inequalities will widen if effective services are offered, or taken up, with greater frequency by wealthier than less wealthy people. The reverse is also true, however, and there is an opportunity for healthcare to reduce social inequalities if it reaches those most in need⁷.

Little is known about pathways into poor health. The National Health Service provides medical care free at point-of-need to all UK residents, but there is scope for inequalities to occur in the pathway from identification of early symptoms through diagnosis and on to effective treatment. Individuals in more deprived social groups may be more reluctant to present to doctors with their symptoms and so may not receive a diagnosis^{8,9}. Diagnosis is a key step that has meaning for both patient and physician in all health systems, and 'diagnostic confusion' may act as a barrier to health care for vulnerable populations^{10,8,11}. Previous studies have found socio-economic variation in either diagnosis or treatment rates, but have not been able to compare inequalities in illness burden, rates of diagnosis and treatment modalities in the same population¹²⁻¹⁴.

The English Longitudinal Study of Ageing (ELSA) provides new data that can be used to identify barriers to equitable receipt of healthcare, and constitutes a unique source of information on illness burden, self-reported medical diagnosis and treatment. Other data sources cover symptoms, or diagnosis, or treatment, but no other single source covers all three. ELSA collects data on symptoms and validated markers of common health conditions, as well as diagnosis and treatment. It also contains detailed socio-demographic information, including direct measures of personal wealth, on a sample selected to be representative of the population of England aged 50 years and older. These data can be used to compare socio-economic inequalities for several conditions, providing insight into a healthcare system with no direct financial barriers to treatment (the National Health Service in England). We aimed to assess socio-economic inequalities in the burden of illness (estimated by validated scales, biomarker, and reported symptoms) of angina, cataract, depression, diabetes and osteoarthritis, and compare them with inequalities in self-reported medical diagnosis and treatment, in order to determine whether key components of health care were received equitably.

Methods

We obtained data from the ELSA cohort, an interview survey of a sample of the population aged 50 years or older in England. The sample was selected from households that had

1
2
3 previously responded to the Health Survey for England, and drawn from selected postcode
4 sectors stratified by health authority and deprivation to be representative of adults aged 50 or
5 more living in private households in England¹⁵. Participants are interviewed in their homes
6 or care homes every two years about a wide range of health, economic and social topics. We
7 used data collected from core participants who had been interviewed in any of four waves of
8 ELSA from wave 2 in 2004-5 until wave 5 in 2010-11. Wave 2 was the first wave to include
9 questions on receipt of quality-indicated healthcare, and information was not collected on
10 every variable in every wave. Ethical approval was received from the London Multi-Centre
11 Research Ethics Committee. We studied five common and important long-term conditions:
12 angina, diabetes, depression, osteoarthritis, and cataract. Effective treatment is freely
13 available for all five conditions from the National Health Service.
14
15

16 Variables

17 We collected data on illness burden, self-reported medical diagnosis and treatment of angina,
18 cataract, depression, diabetes and osteoarthritis. The illness burden for angina was defined as
19 grade 2 on the Rose Angina scale (pain or discomfort in chest when walking at an ordinary
20 pace on the level on most occasions or more often, which makes subject stop or slow down if
21 occurs while walking, and which then goes away within 10 minutes, and which includes
22 either sternum (any level), or left arm and left anterior chest). Illness burden for diabetes was
23 defined as a fasting HbA1c level of >7.5%¹⁶. Illness burden for depression was defined as a
24 score of 3 or more on the eight-item Centre for Epidemiologic Studies Depression Scale
25 (CES-D). The application of these standardised scales in ELSA has been described
26 previously¹. Illness burden for osteoarthritis was defined as self-reported pain in the hip or
27 knee of 5 or more on a scale of 0 to 10¹⁷. Illness burden for cataract was defined broadly as
28 reporting poor vision or blindness. Cataract is responsible for about a quarter of poor vision
29 in the UK, so this measure is the least specific and includes those with other causes of poor
30 vision, such as age-related macular degeneration, which is responsible for about a third of
31 poor vision^{18,19}.
32
33
34

35 A medical diagnosis was considered to exist if a participant answered 'yes' when asked
36 whether a doctor had ever told them they had the condition of interest. For arthritis, a follow-
37 up question asked whether they had been told they had osteoarthritis, rheumatoid or other
38 arthritis.
39

40 Treatment for depression and diabetes was defined by reported achievement of quality of care
41 indicators, derived through a robust process of literature reviews, expert panel assessment and
42 piloting^{20,21}. For depression, the quality indicator was about receipt of treatment since the
43 previous wave: *'if a person is diagnosed with clinical depression, then antidepressive
44 treatment, talking treatment or electroconvulsive treatment should be offered within 2 weeks
45 after diagnosis unless within that period the patient has improved, or unless the patient has
46 substance abuse or dependence, in which case treatment may wait until 8 weeks after the
47 patient is in a drug-or alcohol-free state'*. For diabetes, treatment was measurement of
48 glycosylated haemoglobin or fructosamine levels in the preceding 12 months. Treatment for
49 angina was defined as ever being offered or currently taking beta-blockers (ELSA variables
50 hebeta or hebetc). Treatment for osteoarthritis and cataract were defined as reporting ever
51 having had surgery for the condition. For osteoarthritis this excluded those with hips or knees
52 replaced due to fracture. Data on hip and knee replacements were only available for
53 respondents aged 60 and over, and so respondents aged less than 60 years (n= 3,186) were
54 excluded from the analysis of osteoarthritis.
55
56
57
58
59
60

1
2
3 Wealth was defined as the sum of financial, physical and housing wealth plus state and
4 private pension income. Age was categorised into three groups, 50-59 years, 60-74 years and
5 75 years and older.
6

7 8 **Analysis**

9 We used two approaches to analysis, a main analysis using serial cross sectional data and
10 then a subsidiary analysis using longitudinal data. Multivariable logistic regression analysis
11 was used, with the outcome variables defined as one of illness burden, self-reported medical
12 diagnosis or treatment for each of the five conditions in each cross-sectional wave (STATA
13 statistical software version 12.1). This regression analysis was repeated for each of the four
14 waves of ELSA from 2004 to 2011 separately and then 'overall' for all four waves combined.
15 For the 'overall' analysis, the data were reshaped into 'long' format in Stata statistical
16 software, with each participant having a separate record for each wave. Intra-person
17 correlation of outcomes was accounted for using robust adjustment with Stata, with each
18 participant's unique identifier included in the regression equation as a cluster variable.
19 Missing data were excluded from the analyses.
20

21
22 The independent variables were age group, sex and slope order of inequality. We used the
23 slope order of inequality as an independent variable to estimate the relationship between the
24 outcome measures and the categorised measure of wealth^{22,23}. The slope order of inequality
25 consisted of wealth quintiles with values of 0.1, 0.3, 0.5, 0.7 and 0.9, that is, the midpoints of
26 each quintile on a scale of zero (least wealthy) to one (most wealthy). The slope order of
27 inequality was modelled as a continuous variable, so that the slope or coefficient of a logit
28 linear regression line across all five quintiles represents the difference in outcome between
29 the hypothetically wealthiest and least wealthy participant. Exponentiating this slope
30 coefficient results in an odds ratio, which is the ratio of the odds of the outcome in the
31 wealthiest compared with the least wealthy participant. This odds ratio is also known as a
32 relative index of inequality²². Advantages of this method of quantifying inequality are that it
33 includes all participants, instead of just comparing the highest and lowest quintiles, it
34 accounts for the number of participants in each category and it provides a single overall
35 measure of inequality.
36
37

38 We included all participants in the main cross sectional analysis in order to compare the
39 distribution of illness burden in the whole population with the distributions of diagnoses and
40 treatments in the whole population. This meant that diagnosis was assessed even in those who
41 did not meet the criteria for 'illness burden', and treatment was assessed even in those with
42 no diagnosis. For the subsidiary analysis using longitudinal data, we estimated the odds ratio
43 of receiving a diagnosis by a subsequent wave only for those who had met the criteria for
44 'illness burden' in a previous wave, and then the likelihood of receiving treatment only for
45 those who had received a diagnosis in a previous wave. This was a subsidiary analysis as the
46 numbers of participants that could be followed over time in this manner was small,
47 particularly for treatment in angina and depression.
48
49

50 51 **Results**

52 The whole sample (n=12,765) was composed of participants aged 50 years or more who had
53 responded to at least one wave of ELSA from 2004-5 until 2010-11. The response rate in
54 2004-5 was 82%.^{24,25} In wave 5 (2010-11), self-reported medical diagnosis for all five
55 conditions increased as wealth decreased, for example in depression from 4% in the
56 wealthiest quintile to 11% in the poorest (Table 1). There was little variation between the
57 waves for each of the five conditions (Table 2).
58
59
60

1
2
3
4 The hypothetically least wealthy participant had substantially higher odds than the
5 hypothetically most wealthy of meeting the criteria for 'illness burden' from any of the five
6 conditions at all four time points (overall odds ratios (OR) ranged from 4.2 to 15.1) (Table 3).
7 The least wealthy participant also had higher odds of diagnosis (ORs 1.1 to 4.5) and either no
8 different or relatively small odds of treatment (ORs 0.9 to 2.6) (Table 3, Figure 1).
9

10
11 For angina, the overall odds ratio for meeting the criteria for 'illness burden' was 7.6,
12 indicating that the hypothetically least wealthy individual was seven times more likely to
13 have angina symptoms (defined by the Rose angina scale) than the wealthiest. The odds ratio
14 for self-reported medical diagnosis was 4.5, suggesting that some less wealthy people with
15 angina symptoms had not received a diagnosis of angina, as the expected odds ratio for
16 equitably distributed diagnosis would have been 7.6. The odds ratio for treatment was 3.2,
17 and again the expected odds ratios for equitably distributed treatment would have been 7.6.
18 For depression, the overall odds ratio for illness burden was 6.4, for medical diagnosis was
19 3.3, and for treatment was 2.6, again suggesting that some poorer people with symptoms of
20 depression were less likely to have received a diagnosis or indicated health care, as the
21 expected odds ratios for equitably distributed treatment would have been 6.4.
22
23

24 For diabetes, the overall odds ratio for illness burden was 4.2 and 4.0 for diagnosis,
25 suggesting that for diabetes diagnosis was distributed equitably. However, the odds ratio for
26 treatment was 0.9 and not statistically significantly different from 1, again suggesting that
27 some less wealthy people with medically diagnosed diabetes had not received treatment, as
28 the expected odds ratios for equitably distributed treatment would have been 4.2.
29

30
31 The subsidiary analysis calculated the odds ratios of receiving a diagnosis by a subsequent
32 wave only for those who had met the criteria for 'illness burden' for the relevant long term
33 condition in a previous wave; and then the likelihood of receiving treatment only for those
34 who had received a medical diagnosis in a previous wave. The substantial inequalities in the
35 illness burden of conditions by wealth are identical to Table 3, as expected, and subsequently
36 the numbers of eligible participants dwindle rapidly due to the nested nature of the analysis,
37 with some wide confidence intervals and 9 out of 10 results not statistically significant
38 (Supplemental file 1).
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Characteristics of ELSA participants at wave 5 (2010-11) and self-reported medical diagnosis of angina, cataract, depression, diabetes and osteoarthritis.

		Whole sample	Angina	Cataract	Depression	Diabetes	Osteoarthritis
		N	%	%	%	%	%
Sex	Male	3,886	8.2	13.4	5.4	13.3	19.8
	Female	4,843	6.3	20.4	7.8	9.4	32.9
Age (years)	50-59	1,906	2.2	3.7	10.1	7.2	17.1
	60-74	4,766	5.8	14.5	7.0	11.0	28.1
	75+	2,057	15.0	36.6	2.9	15.0	34.1
Wealth quintile*	1	1,716	3.4	13.8	4.1	6.0	21.5
	2	1,714	4.9	15.5	5.9	8.0	24.2
	3	1,723	6.6	20.1	5.7	11.3	25.7
	4	1,716	8.2	18.6	6.7	13.6	31.6
	5	1,715	12.9	19.2	11.5	16.7	33.1
	missing	145	5.5	9.7	4.8	9.7	20.0
Total		8,729	7.2	17.3	6.7	11.1	27.1

*1=wealthiest quintile, 5=least wealthy quintile

Table 2. Prevalence of illness burden, self-reported medical diagnosis, and treatment for angina, cataract, depression, diabetes and osteoarthritis in four waves of ELSA

	Angina	Cataract	Depression	Diabetes	Osteoarthritis
	N (%)	N (%)	N (%)	N (%)	N (%)
Illness burden					
Wave 2 (2004-5)	397 (4.6)	308 (3.5)	2,037 (23.4)	160 (1.8)	1,106 (12.7)
Wave 3 (2006-7)	300 (3.6)	317 (3.8)	1,929 (23.3)	n/a	917 (11.1)
Wave 4 (2008-9)	300 (3.1)	331 (3.5)	2,049 (21.4)	220 (2.3)	1,088 (11.4)
Wave 5 (2010-11)	254 (2.9)	320 (3.7)	1,956 (22.4)	n/a	1,046 (12.0)
Medical diagnosis					
Wave 2 (2004-5)	668 (7.6)	1,050 (12.1)	402 (4.6)	715 (8.2)	1,861 (21.4)
Wave 3 (2006-7)	591 (7.1)	1,294 (15.7)	490 (5.9)	935 (11.3)	1,952 (23.6)
Wave 4 (2008-9)	645 (6.7)	1,421 (14.8)	601 (6.3)	1,215 (12.7)	2,262 (23.6)
Wave 5 (2010-11)	655 (7.5)	1,566 (17.9)	602 (6.9)	1,413 (16.2)	2,416 (27.7)
Treatment					
Wave 2 (2004-5)	85 (1.0)	535 (6.2)	98 (1.1)	552 (6.4)	202 (2.3)
Wave 3 (2006-7)	n/a	379 (4.9)	n/a	618 (7.5)	141 (1.7)
Wave 4 (2008-9)	n/a	444 (4.6)	155 (1.6)	671 (7.0)	226 (2.4)
Wave 5 (2010-11)	88 (1.0)	646 (7.4)	n/a	748 (8.6)	208 (2.4)
Total number of participants in each wave: wave 2: 8,688; wave 3: 8,268; wave 4: 9,578; wave 5: 8,729					
n/a = data not available for that condition in that wave					

Table 3. Illness burden, self-reported medical diagnosis and treatment of angina, cataract, depression, diabetes and osteoarthritis, comparing the least wealthy with the most wealthy: logistic regression.

		Angina	Cataract	Depression	Diabetes	Osteoarthritis
Odds ratios (95% confidence interval)						
Wave 2* (2004-5)	Illness burden	5.6 (3.8, 8.3)	7.2 (4.5, 11.5)	5.1 (4.3, 6.2)	4.4 (2.5, 8.0)	11.0 (8.1, 14.9)
	Medical diagnosis	2.9 (2.2, 3.9)	1.3 (1.0, 1.6)	4.8 (3.3, 7.0)	3.1 (2.3, 4.2)	1.6 (1.3, 2.0)
	Treatment	2.6 (1.2, 5.7)	1.5 (1.0, 2.2)	0.6 (0.1, 2.9)	0.7 (0.3, 1.5)	1.1 (0.7, 1.9)
Wave 3* (2006-7)	Illness burden	8.7 (5.5, 13.8)	8.2 (5.1, 13.1)	6.9 (5.7, 8.5)		12.7 (9.1, 17.8)
	Medical diagnosis	4.9 (3.6, 6.8)	1.2 (1.0, 1.5)	0.7 (0.4, 1.4)	3.4 (2.6, 4.4)	0.6 (0.4, 0.8)
	Treatment		1.3 (0.8, 1.9)		1.2 (0.6, 2.4)	1.0 (0.6, 1.9)
Wave 4* (2008-9)	Illness burden	6.7 (4.2, 10.5)	5.5 (3.6, 8.6)	5.9 (4.9, 7.1)	3.9 (2.4, 6.4)	14.0 (10.3, 19.1)
	Medical diagnosis	4.3 (3.2, 5.9)	1.1 (0.9, 1.4)	0.7 (0.4, 1.2)	3.9 (3.1, 5.1)	0.6 (0.4, 0.8)
	Treatment		1.1 (0.7, 1.6)	2.4 (1.0, 5.9)	0.2 (0.1, 0.6)	1.0 (0.6, 1.6)
Wave 5* (2010-11)	Illness burden	8.4 (5.1, 13.7)	6.2 (3.9, 9.9)	5.9 (4.8, 7.1)		16.0 (11.7, 21.8)
	Medical diagnosis	5.3 (3.9, 7.3)	1.3 (1.0, 1.5)	1.7 (1.0, 2.8)	4.3 (3.4, 5.4)	0.6 (0.4, 0.8)
	Treatment	3.3 (1.5, 7.3)	1.8 (1.2, 2.6)		0.8 (0.4, 1.6)	1.2 (0.7, 2.0)
Overall†	Illness burden	7.6 (5.4, 10.8)	8.0 (5.4, 11.9)	6.4 (5.5, 7.5)	4.2 (2.6, 6.8)	15.1 (11.4, 20.0)
	Medical diagnosis	4.5 (3.3, 6.0)	1.3 (1.1, 1.5)	3.3 (2.4, 4.5)	4.0 (3.1, 5.2)	1.1 (0.9, 1.3)
	Treatment	3.2 (1.7, 6.0)	1.3 (1.0, 1.8)	2.6 (1.1, 6.1)	0.9 (0.5, 1.4)	1.2 (0.8, 1.6)

*Odds ratios adjusted for age group and sex

†Odds ratios adjusted for age group, sex and unique participant identifier

**Analyses for osteoarthritis excluded those younger than 60 years, as data on osteoarthritis treatment were only collected in those aged 60 or over.

Statistically significant odds ratios (where the 95% confidence intervals do not include 1 before rounding to one decimal place) are shown in bold

1
2
3 **Figure 1.** Illness burden (in blue), self-reported medical diagnosis (in green), and treatment
4 (in red) of angina, cataract, depression, diabetes and osteoarthritis, comparing the least
5 wealthy with the most wealthy: Overall odds ratios (adjusted for age and sex) and 95%
6 confidence bars: logistic regression
7

8
9 INSERT FIGURE 1 HERE

10 11 **Discussion**

12 We found that while there were strong inverse associations between wealth and the burden of
13 illness (based on validated scales, symptoms and biomarker) of a long-term condition, there
14 were smaller or absent inequalities in receipt of self-reported medical diagnosis or treatment
15 for the conditions considered. This suggests that the substantially higher illness burden in less
16 wealthy participants was not matched by appropriately higher levels of diagnosis and
17 treatment, and that equitable receipt of a medical diagnosis may have an important role in
18 reducing inequalities in health.
19

20
21 ELSA is a unique single source of detailed data on socioeconomic status and health, and this
22 is the first study to compare inequalities in illness burden, self-reported medical diagnosis and
23 treatment of long-term conditions in a panel study over time. ELSA used robust measures of
24 individual socio-economic position, and standardised scales and blood biomarker to assess
25 health status. This exploratory study has some limitations and the results should be
26 interpreted with caution and tested in subsequent research. Whilst standardised measures
27 were used to estimate the illness burden of depression, angina and diabetes, symptoms alone
28 were used for osteoarthritis and cataract, and the attributed symptoms were not specific for
29 osteoarthritis and cataract. However, this lack of specificity is unlikely to vary with wealth,
30 and so is not likely to be an important source of bias. Self-reported data may be a source of
31 bias if self-report varies by factors other than objective health status, such as wealth or social
32 experience. This is a recognised problem with some self-reported morbidity data, but is less
33 of a problem with sensory assessment for pain, which is essentially self-perceived, and
34 where self-report is the best means of assessment ²⁶.
35
36

37
38 We have not adjusted for health-related factors that are also more prevalent in poorer
39 populations, such as smoking, obesity and comorbidity, because none of these are a reason
40 for not making a diagnosis. Comorbid conditions are commoner in those with lower socio-
41 economic status, but there is no evidence that comorbidities make a new diagnosis less likely.
42 On the contrary, a higher number of comorbid conditions in older people may be associated
43 with higher quality of care ²⁷. We found different patterns in different conditions, which fits
44 with other research showing that wealth acts differently in different conditions, and for
45 example, has no association with referral for post-menopausal bleeding ²⁸. Major national
46 policy interventions such as the Quality and Outcomes Framework payment for performance
47 scheme in primary care ²⁹ have been associated with improved healthcare for included
48 conditions such as angina and diabetes, more than for excluded conditions such osteoarthritis
49 and poor vision ³⁰⁻³².
50
51

52 The serial cross-sectional analysis of 4 waves of ELSA included all eligible participants in
53 each wave in order to maximise the sample size. This approach meant that some participants
54 with a diagnosed condition would no longer have had symptoms or raised biomarkers, if they
55 were being successfully treated. Examples would be diabetic participants whose blood sugar
56 levels were being successfully controlled by treatment, and participants with successfully
57 treated depression. We therefore checked our main results with the secondary (longitudinal)
58
59
60

1
2
3 analysis, which assessed subsequent diagnosis in those had met the criteria for ‘illness
4 burden’, and subsequent treatment in those with a medical diagnosis, but the number of
5 participants who could be followed through the waves in this way was too small to allow
6 meaningful conclusions to be drawn from the results.
7

8
9 Our results fit with previous findings that a greater proportion of people in deprived groups
10 had Rose angina, but there was no difference in the proportions receiving a general
11 practitioner diagnosis of coronary heart disease¹⁴. Care-seeking behaviour and patient
12 preferences may differ with wealth. Given the same information, patients may want fewer
13 medical interventions than their doctors recommend^{33,34} and pessimism about availability of
14 treatment may make older people reluctant to seek help³⁵. Older people may view living with
15 symptoms (such as pain, or emotional problems) as a normal part of ageing³⁶. The response
16 of the primary care physician may also vary with the wealth of the patient. For example, the
17 physician might be more likely to consider symptoms of breathlessness as a medical problem
18 requiring a diagnosis, whereas aches and pains, poor vision, and low mood might be
19 considered part of the tapestry of life, or the natural ageing process. Comorbidity is more
20 common in deprived populations, and may make diagnosis of all conditions harder for
21 doctors within the constraints of a short consultation³⁷.
22
23

24 At a system level, the results may be partially explained by wealthier people living in areas
25 where there are more healthcare resources. Wennberg introduced the concept of ‘supply-
26 sensitive care’ to describe how the quantity of healthcare resources allocated to a particular
27 population was a major determinant of the frequency of use of health services by that
28 population, and gives an example in which ‘a doubling of the supply of internists or
29 cardiologists results in roughly a halving of the interval between repeat visits’^{38,39}. Where
30 healthcare resources are relatively plentiful, patients with chronic diseases will consult more,
31 use more diagnostic tests, and be referred to hospital more. Further research could helpfully
32 investigate whether those missing out on diagnosis are not accessing health services, or are
33 seeing a doctor but not being diagnosed. The participants were selected to be nationally
34 representative of the population of England, and so the findings are likely to be generalisable
35 to England, but not to countries with different healthcare systems. If validated, our findings
36 that inequalities in receipt of diagnoses are potential barriers to equitable healthcare for five
37 common long-term conditions, suggest that future policy interventions to reduce socio-
38 economic inequalities in healthcare should consider improving access to diagnosis as well as
39 treatment.
40
41
42
43
44
45

46 **Funding statement:** This article presents independent research commissioned by the UK
47 National Institute for Health Research (NIHR) under the Health Services Research
48 programme: HSR Project 10/2002/06 – ‘The dynamics of quality: a national panel study of
49 evidence-based standards’. IL’s work was supported by the NIHR Collaboration for Applied
50 Health Research and Care (CLAHRC) for the South West Peninsula. The views expressed in
51 this publication are those of the authors and not necessarily those of the NHS, the NIHR or
52 the Department of Health.
53
54

55 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at
56 www.icmje.org/coi_disclosure.pdf and declare: all authors had financial support from the
57 National Institute for Health Research for the submitted work, DM had financial support from
58
59
60

1
2
3 Age UK; no financial relationships with any organisations that might have an interest in the
4 submitted work in the previous three years; no other relationships or activities that could
5 appear to have influenced the submitted work.
6

7
8 **Ethics approval:** The English Longitudinal Study of Ageing received ethics approval from
9 the National Research Ethics Service: 09/H0505/124. Participants gave informed consent
10 before taking part.

11
12 **Contributors:** NS contributed to the study design, oversaw data analysis and interpretation,
13 and drafted the paper. NS is guarantor. AH undertook data preparation, analysis and
14 interpretation, and contributed to drafting the paper. LM undertook data preparation and
15 analysis. MB and AC advised on statistical techniques. SR, JC and IL advised on data
16 analysis and interpretation. DM contributed to the study design and advised on data analysis
17 and interpretation. All authors contributed to data interpretation and revised the paper
18 critically.
19

20
21 **Acknowledgements:** Dave Stott and Amander Wellings, representatives of Public and
22 Patient Involvement in Research (PPIRes), brought a helpful lay perspective to this research.

23
24 **Data sharing:** The ELSA dataset and technical documentation are available from the UK
25 Data Service at: <http://discover.ukdataservice.ac.uk/catalogue?sn=5050>.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Reference List

- 1
2
3
4
5 (1) Marmot M, Banks J, Blundell R, Lessof C, Nazroo J. Health, Wealth and Lifestyles of
6 the Older Population in England: the 2002 English Longitudinal Study of Ageing.
7 London: The Institute for Fiscal Studies; 2003.
8
- 9
10 (2) Börsch-Supan A, Brugiavini A, Jürges H, Mackenbach J, Siegris J, Weber G. Health,
11 Ageing and Retirement in Europe. First Results from the Survey of Health, Ageing
12 and Retirement in Europe. Mannheim: Mannheim Research Institute for the
13 Economics of Aging (MEA); 2005.
14
- 15 (3) Hemingway H, Shipley M, Macfarlane P, Marmot M. Impact of socioeconomic status
16 on coronary mortality in people with symptoms, electrocardiographic abnormalities,
17 both or neither: the original Whitehall study 25 year follow up. *J Epidemiol
18 Community Health* 2000; 54(7):510-516.
19
- 20 (4) Wilkinson R, Marmot M. Social determinants of health: the solid facts. 2nd edition
21 ed. Copenhagen: World Health Organisation; 2003.
22
- 23 (5) McKeown T. The role of medicine: dream, mirage or nemesis? 1 ed. London:
24 Nuffield Principal Hospital Trust; 1976.
25
- 26 (6) Bunker JP. The role of medical care in contributing to health improvements within
27 societies. *Int J Epidemiol* 2001; 30(6):1260-1263.
28
- 29 (7) Watt G. The inverse care law today. *Lancet* 2002; 360:252-4.
30
- 31 (8) Richards HM, Reid ME, Watt GCM. Socioeconomic variations in responses to chest
32 pain: qualitative study. *BMJ* 2002; 324(7349):1308.
33
- 34 (9) Gardner K, Chapple A. Barriers to referral in patients with angina: qualitative study.
35 *BMJ* 1999; 319(7207):418-421.
36
- 37 (10) Berger J, Mohr J. A fortunate man: the story of a country doctor. London: Penguin;
38 1967.
39
- 40 (11) Tod AM, Read C, Lacey A, Abbott J. Barriers to uptake of services for coronary heart
41 disease: qualitative. *BMJ* 2001; 323(7306):214.
42
- 43 (12) Chaturvedi N, Ben Shlomo Y. From the surgery to the surgeon: does deprivation
44 influence consultation and operation rates? *Br J Gen Pract* 1995; 45(392):127-131.
45
- 46 (13) Mahomed NN, Barrett JA, Katz JN, Phillips CB, Losina E, Lew RA et al. Rates and
47 outcomes of primary and revision total hip replacement in the United States medicare
48 population. *J Bone Joint Surg Am* 2003; 85-A(1):27-32.
49
- 50 (14) Richards H, McConnachie A, Morrison C, Murray K, Watt G. Social and gender
51 variation in the prevalence, presentation and general practitioner provisional diagnosis
52 of chest pain. *J Epidemiol Community Health* 2000; 54(9):714-718.
53
- 54 (15) Natcen Social Research. English Longitudinal Study of Ageing (ELSA) Wave One to
55 Wave Five User Guide. <http://www.esds.ac>
56
57
58
59
60

uk/doc/5050/mrdoc/pdf/5050_User_Guide_to_the_ELSA_Datasets_Waves_1_to_5
pdf [2012 [cited 2013 Sept. 28];

- (16) Scholes S, Taylor R, Cheshire H, Cox K, Lessof C. Retirement, health and relationships of the older population in England: The 2004 English Longitudinal Study of Ageing. Technical Report P2808. London: National Centre for Social Research; 2008.
- (17) Steel N, Melzer D, Gardener E, McWilliams B. Need for and receipt of hip and knee replacement--a national population survey. *Rheumatology* 2006;(45):1437-1441.
- (18) Evans JR, Fletcher AE, Wormald RPL, Siu-Woon Ng E, Sterling S, Smeeth L et al. Prevalence of partial sight and blindness in people aged 75 years and older in Britain: results from the MRC trial of assessment and management of older people in the community. *Br J Ophthalmol* 2002; 86:795-800.
- (19) Congdon N, O'Colmain B, Klaver CCW, Klein R, Munoz B, Friedman DS et al. Causes and Prevalence of Partial sight and blindness among adults in the United States. *Arch Ophthalmol* 2004; 122:477-485.
- (20) Steel N, Melzer D, Shekelle PG, Wenger NS, Forsyth D, McWilliams BC. Developing quality indicators for older adults: transfer from the USA to the UK is feasible. *Quality and Safety in Health Care* 2004; 13(4):260-264.
- (21) Steel N, Bachmann M, Maisey S, Shekelle P, Breeze E, Marmot M et al. Self reported receipt of care consistent with 32 quality indicators: National population survey of adults aged 50 or more in England. *BMJ* 2008; 337:a957.
- (22) Wagstaff A, Paci P, Van Doorslaer E. On the measurement of inequalities in health. *Soc Sci Med* 1991; 33(5):545-557.
- (23) Bachmann MO, Eachus J, Hopper CD, Davey SG, Propper C, Pearson NJ et al. Socio-economic inequalities in diabetes complications, control, attitudes and health service use: a cross-sectional study. *Diabet Med* 2003; 20(11):921-929.
- (24) Banks J, Breeze E, Lessof C, Nazroo J. Retirement, health and relationships of the older population in England: The 2004 English Longitudinal Study of Ageing (Wave 2). London: The Institute for Fiscal Studies; 2006.
- (25) Cheshire H, Hussey D, Medina J, Pickering K, Wood N, Ward K et al. Financial circumstances, health and well-being of the older population in England: The 2008 English Longitudinal Study of Ageing. Wave 4 Technical Report. London: National Centre for Social Research; 2012.
- (26) Sen A. Health: perception versus observation. *BMJ* 2002; 324(7342):860-861.
- (27) Min LC, Reuben DB, MacLean CH, Shekelle PG, Solomon DH, Higashi T et al. Predictors of Overall Quality of Care Provided to Vulnerable Older People. *J Am Geriatr Soc* 2005; 53(10):1705-1711.
- (28) McBride D, Hardoon S, Walters K, Gilmour S, Raine R. Explaining variation in referral from primary to secondary care: cohort study. *BMJ* 2010; 341.

- 1
2
3 (29) NHS Employers and the General Practitioners Committee. Quality and Outcomes
4 Framework for 2012/13. Guidance for PCOs and practices. London: NHS Employers;
5 2012.
6
7 (30) Gillam S, Steel N. The Quality and Outcomes Framework: where next? BMJ 2013;
8 346.
9
10 (31) Gillam SJ, Siriwardena AN, Steel N. Pay-for-Performance in the United Kingdom:
11 Impact of the Quality and Outcomes Framework - A Systematic Review. The Annals
12 of Family Medicine 2012; 10(5):461-468.
13
14 (32) Steel N, Maisey S, Clark A, Fleetcroft R, Howe A. Quality of clinical primary care
15 and targeted incentive payments: an observational study. Br J Gen Pract
16 2007;(57):449-454.
17
18 (33) Steel N. Thresholds for taking antihypertensive drugs in different professional and lay
19 groups: questionnaire survey. BMJ 2000; 320:1446-7.
20
21 (34) Montgomery AA, Fahey T. How do patients' treatment preferences compare with
22 those of clinicians? Quality in health care 2001; 10 (Suppl I):i39-i43.
23
24 (35) Sanders C, Donovan JL, Dieppe PA. Unmet need for joint replacement: a qualitative
25 investigation of barriers to treatment among individuals with severe pain and
26 disability of the hip and knee. Rheumatology 2004; 43(3):353-357.
27
28 (36) Murray J, Banerjee S, Byng R, Tylee A, Bhugra D, Macdonald A. Primary care
29 professionals' perceptions of depression in older people: a qualitative study. Social
30 Science & Medicine 2006; 63:1363-73.
31
32 (37) Mercer SW, Guthrie B, Furler J, Watt G, Tudor Hart J. Multimorbidity and the
33 inverse care law in primary care. BMJ 2012; 344.
34
35 (38) Wennberg JE. Understanding Geographic Variations in Health Care Delivery. The
36 New England Journal of Medicine 1999; 340(1):52-53.
37
38 (39) Wennberg JE. Unwarranted variations in healthcare delivery: implications for
39 academic medical centres. BMJ 2002; 325(7370):961-964.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



90x139mm (300 x 300 DPI)

1
2
3
4 **Economic inequalities in burden of illness, diagnosis and**
5 **treatment of five long-term conditions in England: panel study.**
6
7
8

9
10 Steel N, Hardcastle A, Bachmann MO, Richards S, Mounce L, Clark A, Lang I, Melzer D,
11 Campbell J.

12
13 N Steel, Clinical Reader¹

14 AC Hardcastle, Senior Research Associate¹

15 MO Bachmann, Professor of Health Services Research¹

16 S H Richards, Senior Lecturer²

17 LTA Mounce, Research Associate²

18 A Clark, Senior Lecturer¹

19 I Lang, Senior Lecturer in Public Health³

20 D Melzer, Professor of Epidemiology and Public Health²

21 J Campbell, Professor of General Practice and Primary Care²

22
23
24 ¹Population Health and Primary Care, Norwich Medical School, University of East Anglia,
25 Norwich NR4 7TJ

26
27 ²University of Exeter Medical School, Smeall Building, St Luke's Campus, Exeter, EX1 2LU

28
29 ³NIHR CLAHRC South West Peninsula, Veysey Building, Salmon Pool Lane, Exeter, EX2
30 4SG

31
32
33 Corresponding author: Nicholas Steel

34 n.steel@uea.ac.uk

35 01603 591161
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective:

We compared the distribution by wealth of self-reported illness burden (estimated from validated scales, biomarker and reported symptoms) for angina, cataract, depression, diabetes and osteoarthritis, with the distribution of self-reported medical diagnosis and treatment. We aimed to determine if the greater illness burden borne by poorer participants was matched by appropriately higher levels of diagnosis and treatment.

Design:

The English Longitudinal Study of Ageing, a panel study of 12,765 participants aged 50 years and older in four waves from 2004 to 2011, selected using a stratified random sample of households in England. Distribution of illness burden, diagnosis and treatment by wealth was estimated using regression analysis.

Outcome measures:

The main outcome measures were odds ratios (ORs) for the illness burden, diagnosis and treatment respectively, adjusted for age, sex and wealth. We estimated the illness burden for angina with the Rose Angina scale, diabetes with fasting glycosylated haemoglobin, depression with the Centre for Epidemiologic Studies Depression Scale, osteoarthritis with self-reported pain and disability, and cataract with self-reported poor vision. Medical diagnoses were self-reported for all conditions. Treatment was defined as beta-blocker prescription for angina, surgery for osteoarthritis and cataract, and receipt of pre-defined effective interventions for diabetes and depression.

Results:

Compared to the wealthiest, the least wealthy participant had substantially higher odds for illness burden from any of the five conditions at all four time points, with odds ratios ranging from 4.2 (95% confidence interval 2.6 to 6.8) for diabetes to 15.1 (11.4 to 20.0) for osteoarthritis. The odds ratios for diagnosis and treatment were smaller in all 5 conditions, and ranged from 0.9 (0.5 to 1.4) for diabetes treatment to 4.5 (3.3 to 6.0) for angina diagnosis.

Conclusions:

The substantially higher illness burden in less wealthy participants was not matched by appropriately higher levels of diagnosis and treatment.

Strengths and limitations of this study

- The English Longitudinal Study of Ageing (ELSA) is a unique single source of detailed ~~longitudinal~~ data on socioeconomic status and health, and this is the first study to compare inequalities in illness burden, self-reported medical diagnosis and treatment of long-term conditions in a ~~longitudinal~~ panel study over time
- Highly detailed measures of individual wealth were used alongside standardised scales and blood biomarker to assess the illness burden of depression, angina and diabetes
- Standardised scales were not included in ELSA for osteoarthritis and cataract, so assessment of illness burden for these two conditions was based on attributed symptoms which were not specific for osteoarthritis and cataract
- The study used self-reported data collected using an extensively tested structured questionnaire, but no information from medical records was collected
- An analysis of pooled data from 4 waves of ELSA was used to maximise the sample size, and the main finding that less wealthy participants are relatively underdiagnosed requires validation in a larger longitudinal study.

Main text

Introduction

Poverty is associated with poor health, poor access to health care and poor health outcomes in many countries and across different health care systems¹⁻³. Much of this variation is caused by recognised broad social determinants of health⁴. Considerable political effort has been directed at attempts to narrow health inequalities by reducing poverty and social exclusion. However, as health care has become more effective at improving health, its potential contribution to ameliorating health inequalities has increased. McKeown demonstrated in the 1970s that health services had contributed little to health improvement⁵, but the same claim could not be made today. The past 30 years have seen the introduction of a wide range of effective interventions, particularly for the prevention and management of chronic disease⁶. Yet although these new interventions improve health, they are not necessarily applied equally across the population. Health inequalities will widen if effective services are offered, or taken up, with greater frequency by wealthier than less wealthy people. The reverse is also true, however, and there is an opportunity for healthcare to reduce social inequalities if it reaches those most in need⁷.

Little is known about pathways into poor health. The National Health Service provides medical care free at point-of-need to all UK residents, but there is scope for inequalities to occur in the pathway from identification of early symptoms through diagnosis and on to effective treatment. Individuals in more deprived social groups may be more reluctant to present to doctors with their symptoms and so may not receive a diagnosis^{8,9}. Diagnosis is a key step that has meaning for both patient and physician in all health systems, and 'diagnostic confusion' may act as a barrier to health care for vulnerable populations^{10,8,11}. Previous studies have found socio-economic variation in either diagnosis or treatment rates, but have not been able to compare inequalities in illness burden, rates of diagnosis and treatment modalities in the same population¹²⁻¹⁴.

The English Longitudinal Study of Ageing (ELSA) provides new data that can be used to identify barriers to equitable receipt of healthcare, and constitutes a unique source of information on illness burden, self-reported medical diagnosis and treatment. Other data sources cover symptoms, or diagnosis, or treatment, but no other single source covers all three. ELSA collects data on symptoms and validated markers of common health conditions, as well as diagnosis and treatment. It also contains detailed socio-demographic information, including direct measures of personal wealth, on a sample selected to be representative of the population of England aged 50 years and older. These data can be used to compare socio-economic inequalities for several conditions, providing insight into a healthcare system with no direct financial barriers to treatment (the National Health Service in England). We aimed to assess socio-economic inequalities in the burden of illness (estimated by validated scales, biomarker, and reported symptoms) of angina, cataract, depression, diabetes and osteoarthritis, and compare them with inequalities in self-reported medical diagnosis and treatment, in order to determine whether key components of health care were received equitably.

Methods

We obtained data from the ELSA cohort, an interview survey of a sample of the population aged 50 years or older in England. The sample was selected from households that had

1
2
3 previously responded to the Health Survey for England, and drawn from selected postcode
4 sectors stratified by health authority and deprivation to be representative of adults aged 50 or
5 more living in private households in England¹⁵. Participants are interviewed in their homes
6 or care homes every two years about a wide range of health, economic and social topics. We
7 used data collected from core participants who had been interviewed in any of four waves of
8 ELSA from wave 2 in 2004-5 until wave 5 in 2010-11. Wave 2 was the first wave to include
9 questions on receipt of quality-indicated healthcare, and information was not collected on
10 every variable in every wave. Ethical approval was received from the London Multi-Centre
11 Research Ethics Committee. We studied five common and important long-term conditions:
12 angina, diabetes, depression, osteoarthritis, and cataract. Effective treatment is freely
13 available for all five conditions from the National Health Service.
14
15

16 Variables

17 We collected data on illness burden, self-reported medical diagnosis and treatment of angina,
18 cataract, depression, diabetes and osteoarthritis. The illness burden for angina was defined as
19 grade 2 on the Rose Angina scale (pain or discomfort in chest when walking at an ordinary
20 pace on the level on most occasions or more often, which makes subject stop or slow down if
21 occurs while walking, and which then goes away within 10 minutes, and which includes
22 either sternum (any level), or left arm and left anterior chest). Illness burden for diabetes was
23 defined as a fasting HbA1c level of >7.5%¹⁶. Illness burden for depression was defined as a
24 score of 3 or more on the eight-item Centre for Epidemiologic Studies Depression Scale
25 (CES-D). The application of these standardised scales in ELSA has been described
26 previously¹. Illness burden for osteoarthritis was defined as self-reported pain in the hip or
27 knee of 5 or more on a scale of 0 to 10¹⁷. Illness burden for cataract was defined broadly as
28 reporting poor vision or blindness. Cataract is responsible for about a quarter of poor vision
29 in the UK, so this measure is the least specific and includes those with other causes of poor
30 vision, such as age-related macular degeneration, which is responsible for about a third of
31 poor vision^{18,19}.
32
33
34

35 A medical diagnosis was considered to exist if a participant answered 'yes' when asked
36 whether a doctor had ever told them they had the condition of interest. For arthritis, a follow-
37 up question asked whether they had been told they had osteoarthritis, rheumatoid or other
38 arthritis.
39

40 Treatment for depression and diabetes was defined by reported achievement of quality of care
41 indicators, derived through a robust process of literature reviews, expert panel assessment and
42 piloting^{20,21}. For depression, the quality indicator was about receipt of treatment since the
43 previous wave: *'if a person is diagnosed with clinical depression, then antidepressive
44 treatment, talking treatment or electroconvulsive treatment should be offered within 2 weeks
45 after diagnosis unless within that period the patient has improved, or unless the patient has
46 substance abuse or dependence, in which case treatment may wait until 8 weeks after the
47 patient is in a drug-or alcohol-free state'*. For diabetes, treatment was measurement of
48 glycosylated haemoglobin or fructosamine levels in the preceding 12 months. Treatment for
49 angina was defined as ever being offered or currently taking beta-blockers (ELSA variables
50 hebeta or hebetc). Treatment for osteoarthritis and cataract were defined as reporting ever
51 having had surgery for the condition. For osteoarthritis this excluded those with hips or knees
52 replaced due to fracture. Data on hip and knee replacements were only available for
53 respondents aged 60 and over, and so respondents aged less than 60 years (n= 3,186) were
54 excluded from the analysis of osteoarthritis.
55
56
57
58
59
60

Wealth was defined as the sum of financial, physical and housing wealth plus state and private pension income. Age was categorised into three groups, 50-59 years, 60-74 years and 75 years and older.

Analysis

We used two approaches to analysis, a main analysis using serial cross sectional data and then a subsidiary analysis using longitudinal data. Multivariable logistic regression analysis was used, with the outcome variables defined as one of illness burden, self-reported medical diagnosis or treatment for each of the five conditions in each cross-sectional wave (STATA statistical software version 12.1). This regression analysis was repeated for each of the four waves of ELSA from 2004 to 2011 separately and then 'overall' for all four waves combined. For the 'overall' analysis, the data were reshaped into 'long' format in Stata statistical software, with each participant having a separate record for each wave. Intra-person correlation of outcomes was accounted for using robust adjustment with Stata, with each participant's unique identifier included in the regression equation as a cluster variable. Missing data were excluded from the analyses.

The independent variables were age group, sex and slope order of inequality. We used the slope order of inequality as an independent variable to estimate the relationship between the outcome measures and the categorised measure of wealth^{22,23}. The slope order of inequality consisted of wealth quintiles with values of 0.1, 0.3, 0.5, 0.7 and 0.9, that is, the midpoints of each quintile on a scale of zero (least wealthy) to one (most wealthy). The slope order of inequality was modelled as a continuous variable, so that the slope or coefficient of a logit linear regression line across all five quintiles represents the difference in outcome between the hypothetically wealthiest and least wealthy participant. Exponentiating this slope coefficient results in an odds ratio, which is the ratio of the odds of the outcome in the wealthiest compared with the least wealthy participant. This odds ratio is also known as a relative index of inequality²². Advantages of this method of quantifying inequality are that it includes all participants, instead of just comparing the highest and lowest quintiles, it accounts for the number of participants in each category and it provides a single overall measure of inequality.

We included all participants in the main cross sectional analysis in order to compare the distribution of illness burden in the whole population with the distributions of diagnoses and treatments in the whole population. This meant that diagnosis was assessed even in those who did not meet the criteria for 'illness burden', and treatment was assessed even in those with no diagnosis. For the subsidiary analysis using longitudinal data, we estimated the odds ratio of receiving a diagnosis by a subsequent wave only for those who had met the criteria for 'illness burden' in a previous wave, and then the likelihood of receiving treatment only for those who had received a diagnosis in a previous wave. This was a subsidiary analysis as the numbers of participants that could be followed over time in this manner was small, particularly for treatment in angina and depression.

Results

The whole sample (n=12,765) was composed of participants aged 50 years or more who had responded to at least one wave of ELSA from 2004-5 until 2010-11. The response rate in 2004-5 was 82%.^{24,25} In wave 5 (2010-11), ~~over half of the sample of 8,729 were women, or were aged between 60 and 74 years (Table 1).~~ Self-reported medical diagnosis for all five conditions increased as wealth decreased, for example in depression from 4% in the

1
2
3 wealthiest quintile to 11% in the poorest (Table 1). There was little variation between the
4 waves for each of the five conditions (Table 2).

5
6 The hypothetically least wealthy participant had substantially higher odds than the
7 hypothetically most wealthy of meeting the criteria for 'illness burden' from any of the five
8 conditions at all four time points (overall odds ratios (OR) ranged from 4.2 to 15.1) (Table 3).
9 The least wealthy participant also had higher odds of diagnosis (ORs 1.1 to 4.5) and either no
10 different or relatively small odds of treatment (ORs 0.9 to 2.6) (Table 3, Figure 1).
11

12
13 For angina, the overall odds ratio for meeting the criteria for 'illness burden' was 7.6,
14 indicating that the hypothetically least wealthy individual was seven times more likely to
15 have angina symptoms (defined by the Rose angina scale) than the wealthiest. The odds ratio
16 for self-reported medical diagnosis was 4.5, suggesting that some less wealthy people with
17 angina symptoms had not received a diagnosis of angina, as the expected odds ratio for
18 equitably distributed diagnosis would have been 7.6. The odds ratio for treatment was 3.2,
19 and again the expected odds ratios for equitably distributed treatment would have been 7.6.
20 For depression, the overall odds ratio for illness burden was 6.4, for medical diagnosis was
21 3.3, and for treatment was 2.6, again suggesting that some poorer people with symptoms of
22 depression were less likely to have received a diagnosis or indicated health care, as the
23 expected odds ratios for equitably distributed treatment would have been 6.4.
24

25
26 For diabetes, the overall odds ratio for illness burden was 4.2 and 4.0 for diagnosis,
27 suggesting that for diabetes diagnosis was distributed equitably. However, the odds ratio for
28 treatment was 0.9 and not statistically significantly different from 1, again suggesting that
29 some less wealthy people with medically diagnosed diabetes had not received treatment, as
30 the expected odds ratios for equitably distributed treatment would have been 4.2.
31

32
33 The subsidiary analysis calculated the odds ratios of receiving a diagnosis by a subsequent
34 wave only for those who had met the criteria for 'illness burden' for the relevant long term
35 condition in a previous wave; and then the likelihood of receiving treatment only for those
36 who had received a medical diagnosis in a previous wave. The substantial inequalities in the
37 illness burden of conditions by wealth are identical to Table 3, as expected, and subsequently
38 the numbers of eligible participants dwindle rapidly due to the nested nature of the analysis,
39 with some wide confidence intervals and 9 out of 10 results not statistically significant
40 (Supplemental file 1).
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Characteristics of ELSA participants at wave 5 (2010-11) and self-reported medical diagnosis of angina, cataract, depression, diabetes and osteoarthritis.

		Whole sample	Angina	Cataract	Depression	Diabetes	Osteoarthritis
		N	%	%	%	%	%
Sex	Male	3,886	8.2	13.4	5.4	13.3	19.8
	Female	4,843	6.3	20.4	7.8	9.4	32.9
Age (years)	50-59	1,906	2.2	3.7	10.1	7.2	17.1
	60-74	4,766	5.8	14.5	7.0	11.0	28.1
	75+	2,057	15.0	36.6	2.9	15.0	34.1
Wealth quintile*	1	1,716	3.4	13.8	4.1	6.0	21.5
	2	1,714	4.9	15.5	5.9	8.0	24.2
	3	1,723	6.6	20.1	5.7	11.3	25.7
	4	1,716	8.2	18.6	6.7	13.6	31.6
	5	1,715	12.9	19.2	11.5	16.7	33.1
	missing	145	5.5	9.7	4.8	9.7	20.0
Total		8,729	7.2	17.3	6.7	11.1	27.1

*1=wealthiest quintile, 5=least wealthy quintile

Table 2. Prevalence of illness burden, self-reported medical diagnosis, and treatment for angina, cataract, depression, diabetes and osteoarthritis in four waves of ELSA

	Angina N (%)	Cataract N (%)	Depression N (%)	Diabetes N (%)	Osteoarthritis N (%)
Illness burden					
Wave 2 (2004-5)	397 (4.6)	308 (3.5)	2,037 (23.4)	160 (1.8)	1,106 (12.7)
Wave 3 (2006-7)	300 (3.6)	317 (3.8)	1,929 (23.3)	n/a	917 (11.1)
Wave 4 (2008-9)	300 (3.1)	331 (3.5)	2,049 (21.4)	220 (2.3)	1,088 (11.4)
Wave 5 (2010-11)	254 (2.9)	320 (3.7)	1,956 (22.4)	n/a	1,046 (12.0)
Medical diagnosis					
Wave 2 (2004-5)	668 (7.6)	1,050 (12.1)	402 (4.6)	715 (8.2)	1,861 (21.4)
Wave 3 (2006-7)	591 (7.1)	1,294 (15.7)	490 (5.9)	935 (11.3)	1,952 (23.6)
Wave 4 (2008-9)	645 (6.7)	1,421 (14.8)	601 (6.3)	1,215 (12.7)	2,262 (23.6)
Wave 5 (2010-11)	655 (7.5)	1,566 (17.9)	602 (6.9)	1,413 (16.2)	2,416 (27.7)
Treatment					
Wave 2 (2004-5)	85 (1.0)	535 (6.2)	98 (1.1)	552 (6.4)	202 (2.3)
Wave 3 (2006-7)	n/a	379 (4.9)	n/a	618 (7.5)	141 (1.7)
Wave 4 (2008-9)	n/a	444 (4.6)	155 (1.6)	671 (7.0)	226 (2.4)
Wave 5 (2010-11)	88 (1.0)	646 (7.4)	n/a	748 (8.6)	208 (2.4)
Total number of participants in each wave: wave 2: 8,688; wave 3: 8,268; wave 4: 9,578; wave 5: 8,729					
n/a = data not available for that condition in that wave					

Table 3. Illness burden, self-reported medical diagnosis and treatment of angina, cataract, depression, diabetes and osteoarthritis, comparing the least wealthy with the most wealthy: logistic regression.

		Angina	Cataract	Depression	Diabetes	Osteoarthritis
Odds ratios (95% confidence interval)						
Wave 2* (2004-5)	Illness burden	5.6 (3.8, 8.3)	7.2 (4.5, 11.5)	5.1 (4.3, 6.2)	4.4 (2.5, 8.0)	11.0 (8.1, 14.9)
	Medical diagnosis	2.9 (2.2, 3.9)	1.3 (1.0, 1.6)	4.8 (3.3, 7.0)	3.1 (2.3, 4.2)	1.6 (1.3, 2.0)
	Treatment	2.6 (1.2, 5.7)	1.5 (1.0, 2.2)	0.6 (0.1, 2.9)	0.7 (0.3, 1.5)	1.1 (0.7, 1.9)
Wave 3* (2006-7)	Illness burden	8.7 (5.5, 13.8)	8.2 (5.1, 13.1)	6.9 (5.7, 8.5)		12.7 (9.1, 17.8)
	Medical diagnosis	4.9 (3.6, 6.8)	1.2 (1.0, 1.5)	0.7 (0.4, 1.4)	3.4 (2.6, 4.4)	0.6 (0.4, 0.8)
	Treatment		1.3 (0.8, 1.9)		1.2 (0.6, 2.4)	1.0 (0.6, 1.9)
Wave 4* (2008-9)	Illness burden	6.7 (4.2, 10.5)	5.5 (3.6, 8.6)	5.9 (4.9, 7.1)	3.9 (2.4, 6.4)	14.0 (10.3, 19.1)
	Medical diagnosis	4.3 (3.2, 5.9)	1.1 (0.9, 1.4)	0.7 (0.4, 1.2)	3.9 (3.1, 5.1)	0.6 (0.4, 0.8)
	Treatment		1.1 (0.7, 1.6)	2.4 (1.0, 5.9)	0.2 (0.1, 0.6)	1.0 (0.6, 1.6)
Wave 5* (2010-11)	Illness burden	8.4 (5.1, 13.7)	6.2 (3.9, 9.9)	5.9 (4.8, 7.1)		16.0 (11.7, 21.8)
	Medical diagnosis	5.3 (3.9, 7.3)	1.3 (1.0, 1.5)	1.7 (1.0, 2.8)	4.3 (3.4, 5.4)	0.6 (0.4, 0.8)
	Treatment	3.3 (1.5, 7.3)	1.8 (1.2, 2.6)		0.8 (0.4, 1.6)	1.2 (0.7, 2.0)
Overall†	Illness burden	7.6 (5.4, 10.8)	8.0 (5.4, 11.9)	6.4 (5.5, 7.5)	4.2 (2.6, 6.8)	15.1 (11.4, 20.0)
	Medical diagnosis	4.5 (3.3, 6.0)	1.3 (1.1, 1.5)	3.3 (2.4, 4.5)	4.0 (3.1, 5.2)	1.1 (0.9, 1.3)
	Treatment	3.2 (1.7, 6.0)	1.3 (1.0, 1.8)	2.6 (1.1, 6.1)	0.9 (0.5, 1.4)	1.2 (0.8, 1.6)


*Odds ratios adjusted for age group and sex

†Odds ratios adjusted for age group, sex and unique participant identifier

**Analyses for osteoarthritis excluded those younger than 60 years, as data on osteoarthritis treatment were only collected in those aged 60 or over.

Statistically significant odds ratios (where the 95% confidence intervals do not include 1) before rounding to one decimal place) are shown in bold

Figure 1. Illness burden (in blue), self-reported medical diagnosis (in green), and treatment (in red) of angina, cataract, depression, diabetes and osteoarthritis, comparing the least wealthy with the most wealthy: Overall odds ratios (adjusted for age and sex) and 95% confidence bars: [logistic regression](#) (~~binomial regression~~)



Discussion

We found that while there were strong inverse associations between wealth and the burden of illness (based on validated scales, symptoms and biomarker) of a long-term condition, there were smaller or absent inequalities in receipt of self-reported medical diagnosis or treatment for the conditions considered. This suggests that the substantially higher illness burden in less wealthy participants was not matched by appropriately higher levels of diagnosis and treatment, and that equitable receipt of a medical diagnosis may have an important role in reducing inequalities in health.

ELSA is a unique single source of detailed ~~longitudinal~~ data on socioeconomic status and health, and this is the first study to compare inequalities in illness burden, self-reported medical diagnosis and treatment of long-term conditions in a ~~longitudinal~~ panel study over time. ELSA used robust measures of individual socio-economic position, and standardised scales and blood biomarker to assess health status. This exploratory study has some limitations and the results should be interpreted with caution and tested in subsequent research. Whilst standardised measures were used to estimate the illness burden of depression, angina and diabetes, symptoms alone were used for osteoarthritis and cataract, and the attributed symptoms were not specific for osteoarthritis and cataract. However, this lack of specificity is unlikely to vary with wealth, and so is not likely to be an important source of bias. Self-reported data may be a source of bias if self-report varies by factors other than objective health status, such as wealth or social experience. This is a recognised problem with some self-reported morbidity data, but is less of a problem with sensory assessment for

1
2
3 pain, which is essentially self-perceived, and where self-report is the best means of
4 assessment²⁶.

5
6 We have not adjusted for health-related factors that are also more prevalent in poorer
7 populations, such as smoking, obesity and comorbidity, because none of these are a reason
8 for not making a diagnosis. Comorbid conditions are commoner in those with lower socio-
9 economic status, but there is no evidence that comorbidities make a new diagnosis less likely.
10 On the contrary, a higher number of comorbid conditions in older people may be associated
11 with higher quality of care²⁷. We found different patterns in different conditions, which fits
12 with other research showing that wealth acts differently in different conditions, and for
13 example, has no association with referral for post-menopausal bleeding²⁸. Major national
14 policy interventions such as the Quality and Outcomes Framework payment for performance
15 scheme in primary care²⁹ have been associated with improved healthcare for included
16 conditions such as angina and diabetes, more than for excluded conditions such osteoarthritis
17 and poor vision³⁰⁻³².

18
19
20 The serial cross-sectional analysis of 4 waves of ELSA included all eligible participants in
21 each wave in order to maximise the sample size. This approach meant that some participants
22 with a diagnosed condition would no longer have had symptoms or raised biomarkers, if they
23 were being successfully treated. Examples would be diabetic participants whose blood sugar
24 levels were being successfully controlled by treatment, and participants with successfully
25 treated depression. We therefore checked our main results with the secondary (longitudinal)
26 analysis, which assessed subsequent diagnosis in those had met the criteria for 'illness
27 burden', and subsequent treatment in those with a medical diagnosis, but the number of
28 participants who could be followed through the waves in this way was too small to allow
29 meaningful conclusions to be drawn from the results.

30
31
32 Our results fit with previous findings that a greater proportion of people in deprived groups
33 had Rose angina, but there was no difference in the proportions receiving a general
34 practitioner diagnosis of coronary heart disease¹⁴. Care-seeking behaviour and patient
35 preferences may differ with wealth. Given the same information, patients may want fewer
36 medical interventions than their doctors recommend^{33,34}, and pessimism about availability of
37 treatment may make older people reluctant to seek help³⁵. Older people may view living with
38 symptoms (such as pain, or emotional problems) as a normal part of ageing³⁶. The response
39 of the primary care physician may also vary with the wealth of the patient. For example, the
40 physician might be more likely to consider symptoms of breathlessness as a medical problem
41 requiring a diagnosis, whereas aches and pains, poor vision, and low mood might be
42 considered part of the tapestry of life, or the natural ageing process. Comorbidity is more
43 common in deprived populations, and may make diagnosis of all conditions harder for
44 doctors within the constraints of a short consultation³⁷.

45
46
47 At a system level, the results may be partially explained by wealthier people living in areas
48 where there are more healthcare resources. Wennberg introduced the concept of 'supply-
49 sensitive care' to describe how the quantity of healthcare resources allocated to a particular
50 population was a major determinant of the frequency of use of health services by that
51 population, and gives an example in which 'a doubling of the supply of internists or
52 cardiologists results in roughly a halving of the interval between repeat visits'^{38,39}. Where
53 healthcare resources are relatively plentiful, patients with chronic diseases will consult more,
54 use more diagnostic tests, and be referred to hospital more. Further research could helpfully
55 investigate whether those missing out on diagnosis are not accessing health services, or are
56
57
58
59
60

1
2
3 seeing a doctor but not being diagnosed. The participants were selected to be nationally
4 representative of the population of England, and so the findings are likely to be generalisable
5 to England, but not to countries with different healthcare systems. If validated, our findings
6 that inequalities in receipt of diagnoses are potential barriers to equitable healthcare for five
7 common long-term conditions, suggest that future policy interventions to reduce socio-
8 economic inequalities in healthcare should consider improving access to diagnosis as well as
9 treatment.
10

11
12
13
14
15 **Funding statement:** This article presents independent research commissioned by the UK
16 National Institute for Health Research (NIHR) under the Health Services Research
17 programme: HSR Project 10/2002/06 – ‘The dynamics of quality: a national panel study of
18 evidence-based standards’. IL’s work was supported by the NIHR Collaboration for Applied
19 Health Research and Care (CLAHRC) for the South West Peninsula. The views expressed in
20 this publication are those of the authors and not necessarily those of the NHS, the NIHR or
21 the Department of Health.
22
23

24 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at
25 www.icmje.org/coi_disclosure.pdf and declare: all authors had financial support from the
26 National Institute for Health Research for the submitted work, DM had financial support from
27 Age UK; no financial relationships with any organisations that might have an interest in the
28 submitted work in the previous three years; no other relationships or activities that could
29 appear to have influenced the submitted work.
30
31

32 **Ethics approval:** The English Longitudinal Study of Ageing received ethics approval from
33 the National Research Ethics Service: 09/H0505/124. Participants gave informed consent
34 before taking part.
35

36 **Contributors:** NS contributed to the study design, oversaw data analysis and interpretation,
37 and drafted the paper. NS is guarantor. AH undertook data preparation, analysis and
38 interpretation, and contributed to drafting the paper. LM undertook data preparation and
39 analysis. MB and AC advised on statistical techniques. SR, JC and IL advised on data
40 analysis and interpretation. DM contributed to the study design and advised on data analysis
41 and interpretation. All authors contributed to data interpretation and revised the paper
42 critically.
43
44

45 **Acknowledgements:** Dave Stott and Amander Wellings, representatives of Public and
46 Patient Involvement in Research (PPIRes), brought a helpful lay perspective to this research.
47

48 **Data sharing:** The ELSA dataset and technical documentation are available from the UK
49 Data Service at: <http://discover.ukdataservice.ac.uk/catalogue?sn=5050>.
50
51
52
53
54
55
56
57
58
59
60

Reference List

- 1
2
3
4
5 (1) Marmot M, Banks J, Blundell R, Lessof C, Nazroo J. Health, Wealth and Lifestyles of
6 the Older Population in England: the 2002 English Longitudinal Study of Ageing.
7 London: The Institute for Fiscal Studies; 2003.
8
- 9
10 (2) Börsch-Supan A, Brugiavini A, Jürges H, Mackenbach J, Siegris J, Weber G. Health,
11 Ageing and Retirement in Europe. First Results from the Survey of Health, Ageing
12 and Retirement in Europe. Mannheim: Mannheim Research Institute for the
13 Economics of Aging (MEA); 2005.
14
- 15 (3) Hemingway H, Shipley M, Macfarlane P, Marmot M. Impact of socioeconomic status
16 on coronary mortality in people with symptoms, electrocardiographic abnormalities,
17 both or neither: the original Whitehall study 25 year follow up. *J Epidemiol
18 Community Health* 2000; 54(7):510-516.
19
- 20 (4) Wilkinson R, Marmot M. Social determinants of health: the solid facts. 2nd edition
21 ed. Copenhagen: World Health Organisation; 2003.
22
- 23 (5) McKeown T. The role of medicine: dream, mirage or nemesis? 1 ed. London:
24 Nuffield Principal Hospital Trust; 1976.
25
- 26 (6) Bunker JP. The role of medical care in contributing to health improvements within
27 societies. *Int J Epidemiol* 2001; 30(6):1260-1263.
28
- 29 (7) Watt G. The inverse care law today. *Lancet* 2002; 360:252-4.
30
- 31 (8) Richards HM, Reid ME, Watt GCM. Socioeconomic variations in responses to chest
32 pain: qualitative study. *BMJ* 2002; 324(7349):1308.
33
- 34 (9) Gardner K, Chapple A. Barriers to referral in patients with angina: qualitative study.
35 *BMJ* 1999; 319(7207):418-421.
36
- 37 (10) Berger J, Mohr J. A fortunate man: the story of a country doctor. London: Penguin;
38 1967.
39
- 40 (11) Tod AM, Read C, Lacey A, Abbott J. Barriers to uptake of services for coronary heart
41 disease: qualitative. *BMJ* 2001; 323(7306):214.
42
- 43 (12) Chaturvedi N, Ben Shlomo Y. From the surgery to the surgeon: does deprivation
44 influence consultation and operation rates? *Br J Gen Pract* 1995; 45(392):127-131.
45
- 46 (13) Mahomed NN, Barrett JA, Katz JN, Phillips CB, Losina E, Lew RA et al. Rates and
47 outcomes of primary and revision total hip replacement in the United States medicare
48 population. *J Bone Joint Surg Am* 2003; 85-A(1):27-32.
49
- 50 (14) Richards H, McConnachie A, Morrison C, Murray K, Watt G. Social and gender
51 variation in the prevalence, presentation and general practitioner provisional diagnosis
52 of chest pain. *J Epidemiol Community Health* 2000; 54(9):714-718.
53
- 54 (15) Natcen Social Research. English Longitudinal Study of Ageing (ELSA) Wave One to
55 Wave Five User Guide. <http://www.esds.ac>
56
57
58
59
60

uk/doc/5050/mrdoc/pdf/5050_User_Guide_to_the_ELSA_Datasets_Waves_1_to_5
pdf [2012 [cited 2013 Sept. 28];

- (16) Scholes S, Taylor R, Cheshire H, Cox K, Lessof C. Retirement, health and relationships of the older population in England: The 2004 English Longitudinal Study of Ageing. Technical Report P2808. London: National Centre for Social Research; 2008.
- (17) Steel N, Melzer D, Gardener E, McWilliams B. Need for and receipt of hip and knee replacement--a national population survey. *Rheumatology* 2006;(45):1437-1441.
- (18) Evans JR, Fletcher AE, Wormald RPL, Siu-Woon Ng E, Sterling S, Smeeth L et al. Prevalence of partial sight and blindness in people aged 75 years and older in Britain: results from the MRC trial of assessment and management of older people in the community. *Br J Ophthalmol* 2002; 86:795-800.
- (19) Congdon N, O'Colmain B, Klaver CCW, Klein R, Munoz B, Friedman DS et al. Causes and Prevalence of Partial sight and blindness among adults in the United States. *Arch Ophthalmol* 2004; 122:477-485.
- (20) Steel N, Melzer D, Shekelle PG, Wenger NS, Forsyth D, McWilliams BC. Developing quality indicators for older adults: transfer from the USA to the UK is feasible. *Quality and Safety in Health Care* 2004; 13(4):260-264.
- (21) Steel N, Bachmann M, Maisey S, Shekelle P, Breeze E, Marmot M et al. Self reported receipt of care consistent with 32 quality indicators: National population survey of adults aged 50 or more in England. *BMJ* 2008; 337:a957.
- (22) Wagstaff A, Paci P, Van Doorslaer E. On the measurement of inequalities in health. *Soc Sci Med* 1991; 33(5):545-557.
- (23) Bachmann MO, Eachus J, Hopper CD, Davey SG, Propper C, Pearson NJ et al. Socio-economic inequalities in diabetes complications, control, attitudes and health service use: a cross-sectional study. *Diabet Med* 2003; 20(11):921-929.
- (24) Banks J, Breeze E, Lessof C, Nazroo J. Retirement, health and relationships of the older population in England: The 2004 English Longitudinal Study of Ageing (Wave 2). London: The Institute for Fiscal Studies; 2006.
- (25) Cheshire H, Hussey D, Medina J, Pickering K, Wood N, Ward K et al. Financial circumstances, health and well-being of the older population in England: The 2008 English Longitudinal Study of Ageing. Wave 4 Technical Report. London: National Centre for Social Research; 2012.
- (26) Sen A. Health: perception versus observation. *BMJ* 2002; 324(7342):860-861.
- (27) Min LC, Reuben DB, MacLean CH, Shekelle PG, Solomon DH, Higashi T et al. Predictors of Overall Quality of Care Provided to Vulnerable Older People. *J Am Geriatr Soc* 2005; 53(10):1705-1711.
- (28) McBride D, Hardoon S, Walters K, Gilmour S, Raine R. Explaining variation in referral from primary to secondary care: cohort study. *BMJ* 2010; 341.

- 1
2
3 (29) NHS Employers and the General Practitioners Committee. Quality and Outcomes
4 Framework for 2012/13. Guidance for PCOs and practices. London: NHS Employers;
5 2012.
6
7 (30) Gillam S, Steel N. The Quality and Outcomes Framework: where next? BMJ 2013;
8 346.
9
10 (31) Gillam SJ, Siriwardena AN, Steel N. Pay-for-Performance in the United Kingdom:
11 Impact of the Quality and Outcomes Framework - A Systematic Review. The Annals
12 of Family Medicine 2012; 10(5):461-468.
13
14 (32) Steel N, Maisey S, Clark A, Fleetcroft R, Howe A. Quality of clinical primary care
15 and targeted incentive payments: an observational study. Br J Gen Pract
16 2007;(57):449-454.
17
18 (33) Steel N. Thresholds for taking antihypertensive drugs in different professional and lay
19 groups: questionnaire survey. BMJ 2000; 320:1446-7.
20
21 (34) Montgomery AA, Fahey T. How do patients' treatment preferences compare with
22 those of clinicians? Quality in health care 2001; 10 (Suppl I):i39-i43.
23
24 (35) Sanders C, Donovan JL, Dieppe PA. Unmet need for joint replacement: a qualitative
25 investigation of barriers to treatment among individuals with severe pain and
26 disability of the hip and knee. Rheumatology 2004; 43(3):353-357.
27
28 (36) Murray J, Banerjee S, Byng R, Tylee A, Bhugra D, Macdonald A. Primary care
29 professionals' perceptions of depression in older people: a qualitative study. Social
30 Science & Medicine 2006; 63:1363-73.
31
32 (37) Mercer SW, Guthrie B, Furler J, Watt G, Tudor Hart J. Multimorbidity and the
33 inverse care law in primary care. BMJ 2012; 344.
34
35 (38) Wennberg JE. Understanding Geographic Variations in Health Care Delivery. The
36 New England Journal of Medicine 1999; 340(1):52-53.
37
38 (39) Wennberg JE. Unwarranted variations in healthcare delivery: implications for
39 academic medical centres. BMJ 2002; 325(7370):961-964.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplemental file 1

Supplemental Table 1. Odds ratios for meeting the ‘illness burden’ criteria for angina, cataract, depression, diabetes and osteoarthritis, medical diagnosis for those estimated to have a condition, and treatment for those with a diagnosis, comparing the least wealthy with the most wealthy: binomial regression

Condition	Adjusted odds ratios* (95% CI)			
	Illness burden (Wave 3)	Medical diagnosis (Wave 4)	Treatment (Wave 5)	N in treatment†
Angina	8.7 (5.5, 13.8)	1.4 (0.5, 4.0)	1.6 (0.3, 9.0)	11
Cataract	8.2 (5.1, 13.1)	1.0 (0.3, 3.1)	2.2 (1.2, 3.8)	83
Osteoarthritis	12.7 (9.1, 17.8)	0.7 (0.3, 1.6)	0.7 (0.3, 1.6)	30
	Adjusted odds ratios* (95% CI)			
	Illness burden (Wave 2)	Medical diagnosis (Wave 3)	Treatment (Wave 4)	N in treatment†
Depression	5.1 (4.3, 6.2)	0.4 (0.1, 1.4)	17.3 (0.5, 604)	12
Diabetes	4.4 (2.5, 8.0)	0.1 (0.0, 3.6)	0.5 (0.2, 1.1)	99

*adjusted for age group and sex

†followed through the waves

Waves used in analysis were the most recent with available data

Odds ratios where the 95% confidence intervals do not include 1 (before rounding to one decimal place) are shown in bold

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1&2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4-6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	6
		(d) If applicable, describe analytical methods taking account of sampling strategy	6
		(e) Describe any sensitivity analyses	6
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6-8
		(b) Give reasons for non-participation at each stage	6-8
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	
Outcome data	15*	Report numbers of outcome events or summary measures	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-9
		(b) Report category boundaries when continuous variables were categorized	7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	7
Discussion			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10-11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.